SCHEMBL2265885

SCHEMBL2265885

Cc1nc(-c2cccc(Cc3nn(-c4cnn(C)c4)ccc3=O)c2)no1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.42
MET P08581 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
HCRTR1 O43613 4/20 0.40
HCRTR2 O43614 4/20 0.40
CACNA2D1 P54289 3/20 0.37
FFAR4 Q5NUL3 1/20 0.35
ENPP2 Q13822 1/20 0.35
SLC6A4 P31645 1/20 0.35
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SPHK2 Q9NRA0 1/20 0.34
SPHK1 Q9NYA1 1/20 0.34
CHRNA7 P36544 1/20 0.33
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2264608 0.89 RAB9A (0.37) DAOL3MBTL1MEN1NPC1RAB9A
SCHEMBL2261213 0.88 RAB9A (0.38) L3MBTL1MEN1NPC1RAB9AKMT2A
SCHEMBL2271679 0.87 RAB9A (0.36) DAOL3MBTL1ENPP2MEN1NPC1
SCHEMBL2271901 0.86 PPARA (0.39) L3MBTL1MEN1NPC1RAB9AKMT2A
SCHEMBL2222276 0.86 GAA (0.36) DAOMETHCRTR1HCRTR2SLC6A4
SCHEMBL2221573 0.86 RAB9A (0.36) L3MBTL1MEN1NPC1RAB9AKMT2A
SCHEMBL2273589 0.85 PARP1 (0.48) METHCRTR1HCRTR2ENPP2SPHK2
SCHEMBL12516405 0.85 MET (0.40) METENPP2MEN1KMT2APPARG
SCHEMBL2270320 0.85 IRAK4 (0.37) L3MBTL1MEN1NPC1RAB9AKMT2A
SCHEMBL12518123 0.84 ALDH1A1 (0.44) NPC1RAB9AKMT2ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US claimed
EP-2515657-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-10-31 EP disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
WO-2011084402-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264735-A1 TYROSINE KINASE INHIBITORS ABL1, MET, ERBB2 DAO 1716/4885MET 2/4885L3MBTL1 1158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.